277 related articles for article (PubMed ID: 23154587)
1. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
Yanagi M; Tamura K; Fujikawa T; Wakui H; Kanaoka T; Ohsawa M; Azushima K; Maeda A; Kobori H; Umemura S
Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
[TBL] [Abstract][Full Text] [Related]
3. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease.
Uneda K; Tamura K; Wakui H; Azushima K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Ohsawa M; Fujikawa T; Umemura S
Clin Exp Hypertens; 2016; 38(8):738-743. PubMed ID: 27936941
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
Moriyama T; Tsuruta Y; Kojima C; Itabashi M; Sugiura H; Takei T; Ogawa T; Uchida K; Tsuchiya K; Nitta K
Int Urol Nephrol; 2012 Jun; 44(3):841-5. PubMed ID: 21626132
[TBL] [Abstract][Full Text] [Related]
5. Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.
Kario K; Saito I; Kushiro T; Teramukai S; Mori Y; Hiramatsu K; Kobayashi F; Shimada K
J Clin Hypertens (Greenwich); 2013 Aug; 15(8):555-61. PubMed ID: 23889717
[TBL] [Abstract][Full Text] [Related]
6. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
7. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
Tofé Povedano S; García De La Villa B
J Clin Hypertens (Greenwich); 2009 Aug; 11(8):426-31. PubMed ID: 19695030
[TBL] [Abstract][Full Text] [Related]
8. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
[TBL] [Abstract][Full Text] [Related]
9. How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?
Miura S; Saku K
Hypertens Res; 2013 Mar; 36(3):194-5. PubMed ID: 23171955
[No Abstract] [Full Text] [Related]
10. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
Omboni S; Malacco E; Mallion JM; Fabrizzi P; Volpe M
High Blood Press Cardiovasc Prev; 2014 Mar; 21(1):1-19. PubMed ID: 24435506
[TBL] [Abstract][Full Text] [Related]
11. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan/amlodipine: a review of its use in the management of hypertension.
Kreutz R
Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
[TBL] [Abstract][Full Text] [Related]
16. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Daikuhara H; Fukunaga K; Ohshima T
Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
[TBL] [Abstract][Full Text] [Related]
17. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Yasuda T; Endoh M; Suzuki D; Yoshimura A; Ideura T; Tamura K; Kamata K; Toya Y; Umemura S; Kimura K;
Hypertens Res; 2013 Mar; 36(3):240-6. PubMed ID: 23154591
[TBL] [Abstract][Full Text] [Related]
18. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
20. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
